Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering-Plough has announced that Nippon Organon, part of Schering-Plough, has filed a new drug application with the Japanese Ministry of Health, Labour and Welfare seeking marketing approval for sugammadex, its novel selective relaxant binding agent.
Subscribe to our email newsletter
Sugammadex is specifically designed to rapidly reverse the effects of certain muscle relaxants, rocuronium bromide (marketed in the US as Zemuron and in Japan as Eslax), as well as vecuronium bromide (marketed in Japan as Musculax). Muscle relaxants are used as part of general anesthesia during surgical procedures.
Schering-Plough acquired sugammadex through its combination with Organon BioSciences on November 19, 2007.